Last reviewed · How we verify
Aramine (METARAMINOL)
Aramine (generic name: METARAMINOL) is a Indirectly Acting Sympathomimetic Amines Small molecule drug developed by Merck. It is currently FDA-approved (first approved 1954) for Low blood pressure.
Aramine is a small molecule medication. It is also known by the synonyms METARAMINOL.
At a glance
| Generic name | METARAMINOL |
|---|---|
| Sponsor | Merck |
| Drug class | Indirectly Acting Sympathomimetic Amines |
| Target | Macrophage migration inhibitory factor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Low blood pressure
Common side effects
Key clinical trials
- Comparison of the Efficacy of Continuous Metaraminol Infusion Versus Continuous Norepinephrine Infusion for the Prevention of Hypotension During Cesarean Section Under Spinal Anaesthesia. A Randomised Controlled Trial. (NA)
- Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke (NA)
- Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section (PHASE4)
- Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)
- Effect of Three Weight-adjusted Vasopressors for Elective Cesarean Delivery (PHASE4)
- Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean (PHASE3)
- Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation (NA)
- Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aramine CI brief — competitive landscape report
- Aramine updates RSS · CI watch RSS
Frequently asked questions about Aramine
What is Aramine?
Aramine (METARAMINOL) is a Indirectly Acting Sympathomimetic Amines drug developed by Merck, indicated for Low blood pressure.
What is Aramine used for?
Aramine is indicated for Low blood pressure.
Who makes Aramine?
Aramine is developed and marketed by Merck.
What is the generic name of Aramine?
METARAMINOL is the generic (nonproprietary) name of Aramine.
What drug class is Aramine in?
Aramine belongs to the Indirectly Acting Sympathomimetic Amines class. See all Indirectly Acting Sympathomimetic Amines drugs at /class/indirectly-acting-sympathomimetic-amines.
When was Aramine approved?
Aramine was first approved on 1954.
What development phase is Aramine in?
Aramine is FDA-approved (marketed).
What does Aramine target?
Aramine targets Macrophage migration inhibitory factor and is a Indirectly Acting Sympathomimetic Amines.
Related
- Drug class: All Indirectly Acting Sympathomimetic Amines drugs
- Target: All drugs targeting Macrophage migration inhibitory factor
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Low blood pressure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing